Queen Mary University London Recruits Patients for Heart Disease Clinical Trial


Queen Mary University of London is recruiting patients for a cholesterol-lowering drug for patients intolerant to statins.

Reports MedicalXpress, the CLEAR Outcomes study is recruiting 14,000 patients worldwide from 1000 sites located in over 30 countries (including the UK).  Studying whether Bempedoic acid reduces the risk for cardiovascular disease, this article focuses on London.  Mary Salim, 72 was put on statins post heart attack 15 years ago.  However, Ms. Salim wasn’t able to tolerate statins—and she attempted to consume many varieties of the drug.

What is Bempedoic Acid?

It is a drug under development by Esperion Therapeutics for the treatment of hypercholesterolemia. It has thus far been well-tolerated in patients and has shown to be safe and efficacious in lowering bad cholesterol. As of early 2019, its effects on cardiovascular morbidity and mortality have not been determined, but studies are under way.

Investigator Comments

Lead researcher Dr. Manish Saxena from Queen Mary University of London said, “Statins are effective in lowering bad cholesterol in the body and prevent heart attacks and strokes. Unfortunately, a small number of patients are unable to ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee